Moderna-Merck personalised cancer vaccine takes step closer to market after trial success, could be available next year
The vaccine, known as antisera, was tested in combination with Merck's established immunotherapy drug Keytruda
This article was aggregated from Business Today. Continue reading for the complete story.
Read on Business Today